9,515 results match your criteria Alimentary Pharmacology and Therapeutics[Journal]


Fewer gastrointestinal bleeds with ticagrelor and prasugrel compared with clopidogrel in patients with acute coronary syndrome following percutaneous coronary intervention.

Aliment Pharmacol Ther 2020 Jul 13. Epub 2020 Jul 13.

Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Rochester, MN, USA.

Background: Gastrointestinal bleeding (GIB) frequently occurs following percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS) with the prescription of P2Y inhibiting antiplatelet agents. Compared with clopidogrel, the newer P2Y inhibitors lower major adverse cardiac events with similar or possibly higher major bleeding events. The comparative GIB rates of these medications remains poorly understood. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15790DOI Listing

Randomised clinical trial: oesophageal radiofrequency energy delivery versus sham for PPI-refractory heartburn.

Aliment Pharmacol Ther 2020 Jul 13. Epub 2020 Jul 13.

Gastroenterology Department, CHU de Nantes, Institut des Maladies de l'Appareil Digestif (IMAD), CIC1413, Université de Nantes, Nantes, France.

Background: Oesophageal radiofrequency has been shown to reduce use of proton pump inhibitors (PPIs) in patients with gastro-oesophageal reflux disease responding to PPIs.

Aim: To determine the efficacy of oesophageal radiofrequency in patients with PPI-refractory heartburn.

Methods: A randomised, double-blind, sham-controlled multicentre study was designed to assess the efficacy of oesophageal radiofrequency in PPI non-responding patients with heartburn. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15936DOI Listing

Letter: ciclosporin and vedolizumab for steroid-refractory ulcerative colitis.

Aliment Pharmacol Ther 2020 Aug;52(3):578-579

First Department of Medicine, University of Szeged Faculty of Medicine, Szeged, Hungary.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15896DOI Listing

Letter: combination of biologics in inflammatory bowel diseases. Authors' reply.

Aliment Pharmacol Ther 2020 Aug;52(3):568-569

Division of Gastroenterology, Department of Medicine, UCSD Inflammatory Bowel Disease Center, La Jolla, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15919DOI Listing

Letter: ustekinumab dose intensification for loss of response-should we re-induce before shortening the dose interval? Author's reply.

Authors:
Uri Kopylov

Aliment Pharmacol Ther 2020 Aug;52(3):565-566

Department of Gastroenterology, Sheba Medical Center, Tel Hashomer, Israel.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15892DOI Listing

Letter: moderate levels of serum hepatitis B virus DNA alone are not associated with increased risk of hepatocellular carcinoma in chronic hepatitis B patients. Authors' reply.

Aliment Pharmacol Ther 2020 Aug;52(3):576-577

Department of Gastroenterology, Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15881DOI Listing

Editorial: early TIPSS in patients with cirrhosis and acute variceal bleeding-the plot thickens!

Aliment Pharmacol Ther 2020 Aug;52(3):551-554

Liver Unit, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15904DOI Listing

Editorial: balancing safety and efficacy-6-TGN thresholds in NUDT15 intermediate metabolisers treated with thiopurines.

Aliment Pharmacol Ther 2020 Aug;52(3):554-555

Department of Gastroenterology, The Alfred Hospital, Melbourne, Vic, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15922DOI Listing

Letter: is unrealised adult height resulting from paediatric Crohn's disease associated with a potential reduction in lifetime earnings?

Aliment Pharmacol Ther 2020 Aug;52(3):559-560

Division of Gastroenterology, Hepatology and Nutrition, Boston Children's Hospital, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15828DOI Listing

Letter: liver disease and COVID-19-not the perfect storm. Authors' reply".

Aliment Pharmacol Ther 2020 Aug;52(3):574-575

Gastroenterology and Hepatology Department, Centro Hospitalar Sao Joao, Porto, Portugal.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15886DOI Listing

Letter: early TIPSS in acute variceal bleed-debate continues.

Aliment Pharmacol Ther 2020 Aug;52(3):579-580

Department of Gastroenterology and Human Nutrition, All India Institute of Medical Sciences, New Delhi, India.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15909DOI Listing

Editorial: which factors influence HBsAg levels in HBV-infected patients?

Aliment Pharmacol Ther 2020 Aug;52(3):547-548

Institute of Medical Virology, Justus Liebig University Giessen, National Reference Center for Hepatitis B Viruses and Hepatitis D Viruses, Giessen, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15864DOI Listing

Letter: faecal microbiota transplantation for IBS.

Aliment Pharmacol Ther 2020 Aug;52(3):556-557

Microbiome Treatment Centre, University of Birmingham, Birmingham, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15824DOI Listing

Letter: ustekinumab dose intensification for loss of response-should we re-induce before shortening the dose interval?

Aliment Pharmacol Ther 2020 Aug;52(3):564-565

Department of Gastroenterology, Eastern Health, Melbourne, Vic., Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15883DOI Listing

Letter: liver disease and COVID-19-not the perfect storm.

Aliment Pharmacol Ther 2020 Aug;52(3):572-574

Division of Digestive Diseases, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15872DOI Listing

Letter: is unrealised adult height resulting from paediatric Crohn's disease associated with a potential reduction in lifetime earnings? Authors' reply.

Aliment Pharmacol Ther 2020 Aug;52(3):560-561

Division of Clinical Epidemiology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15899DOI Listing

Letter: choosing between ustekinumab and vedolizumab in anti-TNF refractory Crohn's disease-the devil is in the detail. Authors' reply.

Aliment Pharmacol Ther 2020 Aug;52(3):563-564

Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Université Paris Saclay, Le Kremlin Bicêtre, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15888DOI Listing

Editorial: pancreatic cancer risk in inflammatory bowel diseases-it's all relative.

Aliment Pharmacol Ther 2020 Aug;52(3):550-551

Division of Gastroenterology, University of California San Diego, La Jolla, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15877DOI Listing

Editorial: a need for glucose monitoring on prokinetic treatment with a ghrelin agonist in diabetic gastroparesis?

Authors:
William L Hasler

Aliment Pharmacol Ther 2020 Aug;52(3):545-546

Division of Gastroenterology and Hepatology, University of Michigan Health System, Ann Arbor, MI, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15792DOI Listing

Editorial: a need for glucose monitoring on prokinetic treatment with a ghrelin agonist in diabetic gastroparesis? Author's reply.

Aliment Pharmacol Ther 2020 Aug;52(3):546-547

Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15866DOI Listing

Letter: ACE2, Rho kinase inhibition and the potential role of vitamin D against COVID-19.

Aliment Pharmacol Ther 2020 Aug;52(3):577-578

Nephrology, Dialysis and Transplantation Unit, Department of Medicine, University of Padova, Padova, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15895DOI Listing

Letter: choosing between ustekinumab and vedolizumab in anti-TNF refractory Crohn's disease-the devil is in the detail.

Aliment Pharmacol Ther 2020 Aug;52(3):561-562

Department of Gastroenterology, Eastern Health, Melbourne, Vic., Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15862DOI Listing

Letter: combination of biologics in inflammatory bowel diseases.

Aliment Pharmacol Ther 2020 Aug;52(3):566-567

Department of Gastroenterology, Amiens University Hospital, Picardie University, Amiens, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15891DOI Listing

Editorial: which factors influence HBsAg levels in HBV-infected patients? Authors' reply.

Aliment Pharmacol Ther 2020 Aug;52(3):549-550

Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15910DOI Listing

Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease.

Aliment Pharmacol Ther 2020 Jul 13. Epub 2020 Jul 13.

La Jolla, CA, USA.

Background: Direct comparisons are lacking between vedolizumab and tumour necrosis factor (TNF)-antagonist therapy in Crohn's disease (CD).

Aim: To compare safety and effectiveness of vedolizumab and TNF-antagonist therapy in adult CD patients.

Methods: Retrospective observational cohort (May 2014-December 2017) propensity score-weighted comparison of vedolizumab vs TNF-antagonist therapy (infliximab, adalimumab, certolizumab) in CD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15921DOI Listing

Systematic review with meta-analysis: liver manifestations and outcomes in COVID-19.

Aliment Pharmacol Ther 2020 Jul 8. Epub 2020 Jul 8.

Department of Gastroenterology, Asian Institute of Gastroenterology, Hyderabad, India.

Background: The incidence of elevated liver chemistries and the presence of the pre-existing chronic liver disease (CLD) have been variably reported in COVID-19.

Aims: To assess the prevalence of CLD, the incidence of elevated liver chemistries and the outcomes of patients with and without underlying CLD/elevated liver chemistries in COVID-19.

Methods: A comprehensive search of electronic databases from 1 December 2019 to 24 April 2020 was done. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15916DOI Listing

Review article: The impact of liver-directed therapies on the atherogenic risk profile in non-alcoholic steatohepatitis.

Aliment Pharmacol Ther 2020 Jul 8. Epub 2020 Jul 8.

Division of Gastroenterology and Hepatology, Virginia Commonwealth University, Richmond, VA, USA.

Background: Patients with non-alcoholic fatty liver disease (NAFLD), the most common cause of chronic liver disease, are at higher risk of cardiovascular disease (CVD) and associated mortality. Therefore, it is important to understand how new therapies for non-alcoholic steatohepatitis (NASH) may impact CVD risk factors in these patients.

Aims: To summarise the effects of drug therapies on lipid and lipoprotein levels in patients with NASH and provide insight into the potential mechanisms for the observed changes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15935DOI Listing

Liver involvement is not associated with mortality: results from a large cohort of SARS-CoV-2 positive patients.

Aliment Pharmacol Ther 2020 Jul 6. Epub 2020 Jul 6.

Internal Medicine, Gastroenterology and Hepatology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.

Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is frequently associated with liver tests abnormalities.

Aims: To describe the evolution of liver involvement during SARS-CoV-2 infection and its effect on clinical course and mortality.

Methods: Data of 515 SARS-CoV-2 positive patients were collected at baseline and during follow-up, last evaluation or death. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15996DOI Listing

Review article: prognostic significance of body composition abnormalities in patients with cirrhosis.

Aliment Pharmacol Ther 2020 Jul 3. Epub 2020 Jul 3.

Division of Gastroenterology & Liver Unit, University of Alberta Hospital, Edmonton, AB, Canada.

Background: Recent advances in evaluation of body composition show body mass index to be inadequate in differentiating between body compartments in cirrhosis. Given the limitations of body mass index, body composition evaluation using computed tomography has been increasingly used as a non-invasive clinical tool with prognostic value. Another factor influencing prognosis includes sex-specific differences in body composition that are seen in cirrhosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15927DOI Listing

Factors associated with the biphasic kinetics of serum HBV RNA in patients with HBeAg-positive chronic hepatitis B treated with nucles(t)ide analogues.

Aliment Pharmacol Ther 2020 Jul 1. Epub 2020 Jul 1.

State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China.

Background: Serum hepatitis B virus (HBV) RNA is a novel biomarker for evaluating treatment response. Detailed information regarding serum HBV RNA kinetics during treatment with nucles(t)ide analogues (NAs) is limited.

Aims: To ascertain serum HBV RNA kinetics during long-term NAs treatment and identify associated factors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15890DOI Listing

Sex disparities in presentation and prognosis of 1110 patients with hepatocellular carcinoma.

Aliment Pharmacol Ther 2020 Jun 29. Epub 2020 Jun 29.

Division of Digestive and Liver Diseases, Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, USA.

Background: Although sex disparities in hepatocellular carcinoma (HCC) incidence have been well described, there are limited data examining sex disparities in HCC prognosis.

Aim: To characterise sex differences in HCC presentation and prognosis.

Methods: We performed a retrospective study of consecutive patients (n = 1110, 23. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15917DOI Listing

Association between diabetes mellitus and hepatic encephalopathy in patients with cirrhosis.

Aliment Pharmacol Ther 2020 Aug 29;52(3):527-536. Epub 2020 Jun 29.

Department of Internal Medicine I, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany.

Background: Diabetes mellitus may lead to increased serum ammonia and systemic inflammation thereby promoting hepatic encephalopathy (HE).

Aim: To investigate the potential association between diabetes mellitus/glycaemic control and the presence of covert HE as well as the development of overt HE in a prospective setting.

Methods: A total of 240 patients with liver cirrhosis were included into this prospective cohort study and followed for a median of 17 months. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15915DOI Listing

Clinical assessment for high-risk patients with non-alcoholic fatty liver disease in primary care and diabetology practices.

Aliment Pharmacol Ther 2020 Aug 29;52(3):513-526. Epub 2020 Jun 29.

Washington, DC, USA.

Background: Primary care practitioners (PCPs) and diabetologists are at the frontline of potentially encountering patients with NASH. Identification of those at high risk for adverse outcomes is important.

Aim: To provide practical guidance to providers on how to identify these patients and link them to specialty care. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15830DOI Listing

Adjustment of azathioprine dose should be based on a lower 6-TGN target level to avoid leucopenia in NUDT15 intermediate metabolisers.

Aliment Pharmacol Ther 2020 Aug 29;52(3):459-470. Epub 2020 Jun 29.

Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

Background: The association between NUDT15 polymorphisms and thiopurine-induced leucopenia is well known.

Aim: To investigate the association between NUDT15 polymorphisms and time-to-leucopenia in paediatric patients with inflammatory bowel disease (IBD) receiving azathioprine and to determine the relationship between NUDT15 polymorphisms and 6-thioguanine nucleotide (6-TGN) levels.

Methods: This retrospective observational study included Korean paediatric patients with IBD who were treated with azathioprine and underwent NUDT15 and TPMT genotyping. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15810DOI Listing
August 2020
5.727 Impact Factor

Review article: chronic liver disease and pregnancy.

Aliment Pharmacol Ther 2020 Aug 29;52(3):420-429. Epub 2020 Jun 29.

Liver Unit, Queen Elizabeth Hospital, Birmingham, UK.

Background: The prevalence of chronic liver disease in women of child bearing age is increasing, leading to a higher incidence of pregnancy in this cohort. Chronic medical conditions have a significant adverse effect on maternal morbidity and mortality. To date, reviews on this topic have been written either from a hepatology or obstetrics viewpoint, and no specific guidelines are available solely for the management of chronic liver disease in pregnancy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15908DOI Listing

Regular use of proton pump inhibitor and risk of rheumatoid arthritis in women: a prospective cohort study.

Aliment Pharmacol Ther 2020 Aug 29;52(3):449-458. Epub 2020 Jun 29.

Shatin, Hong Kong.

Background: Proton pump inhibitors (PPIs) have a significant impact on the gut microbiome, which in turn, might increase the risk of rheumatoid arthritis (RA).

Aim: To evaluate regular use of PPIs and risk of RA.

Methods: This is a prospective analysis of the US nurses who reported PPI use data, and were free of RA from the Nurses' Health Study (NHS 2002-2014) and NHS II (2003-2015). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15834DOI Listing

Editorial: improving precision of iron deficiency diagnosis in inflammatory bowel disease.

Aliment Pharmacol Ther 2020 Jul;52(2):400

Department of Gastroenterology, Akershus University Hospital, Lørenskog, Norway.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15809DOI Listing

Editorial: transperineal ultrasound in addition to a transabdominal ultrasound in ulcerative colitis-one more arrow in the quiver of non-invasive diagnostics.

Aliment Pharmacol Ther 2020 Jul;52(2):401-402

Department of Radiology, Mallinckrodt Institute of Radiology, Washington University in Saint Louis, St. Louis, MO, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15816DOI Listing

Letter: bone fracture risk among older long-term users of proton pump inhibitors. Authors' reply.

Aliment Pharmacol Ther 2020 Jul;52(2):408

Division of Gastroenterology and Hepatology, Weill Cornell Medicine, NYC, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15805DOI Listing

Editorial: simultaneous, prolonged monitoring of the acid pocket and oesophageal reflux. Authors' reply.

Aliment Pharmacol Ther 2020 Jul;52(2):398-399

School of Medical Sciences, Universiti Sains Malaysia, Kota Bahru, Malaysia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15835DOI Listing

Editorial: transperineal ultrasound in addition to a transabdominal ultrasound in ulcerative colitis-one more arrow in the quiver of non-invasive diagnostics. Authors' reply.

Aliment Pharmacol Ther 2020 Jul;52(2):403

Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Tokyo, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15871DOI Listing
July 2020
5.727 Impact Factor

Editorial: no man's oesophagus is an island-authors' reply.

Aliment Pharmacol Ther 2020 Jul;52(2):396-397

University of Calgary, Calgary, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15831DOI Listing
July 2020
5.727 Impact Factor

Editorial: no man's oesophagus is an island.

Aliment Pharmacol Ther 2020 Jul;52(2):395-396

Mayo Clinic, Rochester, MN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15799DOI Listing

Editorial: PNPLA3 genotype and liver diseases-more than non-alcoholic fatty liver disease.

Aliment Pharmacol Ther 2020 Jul;52(2):390-391

Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15788DOI Listing

Editorial: gut microbiota profile in patients with autoimmune hepatitis-a clue for adjunctive probiotic therapy?

Aliment Pharmacol Ther 2020 Jul;52(2):392-394

Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15795DOI Listing
July 2020
5.727 Impact Factor

Editorial: simultaneous prolonged monitoring of the acid pocket and oesophageal reflux.

Aliment Pharmacol Ther 2020 Jul;52(2):397-398

Division of Gastroenterology and Hepatology, Medical University of South Carolina, Charleston, SC, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15807DOI Listing

Editorial: diagnostic precision of iron deficiency in inflammatory bowel disease. Authors' reply.

Aliment Pharmacol Ther 2020 Jul;52(2):401

Department of Hepato-Gastroenterology and Inserm NGERE, University Hospital of Nancy, University of Lorraine, Vandoeuvre-lès-Nancy, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15832DOI Listing

Editorial: gut microbiota profile in patients with autoimmune hepatitis-a clue for adjunctive probiotic therapy? Authors' reply.

Aliment Pharmacol Ther 2020 Jul;52(2):394-395

1st Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15819DOI Listing